Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: A retrospective database analysis in the United States

Endocrine Practice

Volumn 18, Issue 5, 2012, Pages 700-711

  Pawaskar, Manjiri ^a   Li, Qian ^b   Hoogwerf, Byron J ^a   Reynolds, Matthew W ^b   Lee, Lauren J ^a,d   Fonseca, Vivian ^c  

^a ELI LILLY AND COMPANY   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c TULANE UNIVERSITY   (United States)

^d DAIICHI SANKYO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; EXENDIN 4; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRESCRIPTION; RETROSPECTIVE STUDY; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES;

EID: 84867390400     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP11367.OR     Document Type: Article

References (22)

1. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care. 2011;34(Suppl 1): S11-S61.
2. Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia. 1999;42:406-412.
3. van Avendonk MJ, Rutten GE. Insulin therapy in type 2 diabetes: What is the evidence? Diabetes Obes Metab. 2009;11:415-432.
4. Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc; 2010.
5. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-Treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-2635.
6. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-Treated patients with type 2 diabetes. Diabetes Care. 2005; 28:1092-1100.
7. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083-1091.
8. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24:275-286.
9. Zinman B, Hoogwerf BJ, Durán García S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: A randomized trial. Ann Intern Med. 2007;146:477-485.
10. Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30:1448-1460.
11. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-Treated patients with type 2 diabetes: A randomized, controlled trial. Ann Intern Med. 2011;154:103-112.
12. Yoon NM, Cavaghan MK, Brunelle RL, Roach P. Exenatide added to insulin therapy: A retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther. 2009;31:1511-1523.
13. Thong KY, Jose B, Sukumar N, et al. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*. Diabetes Obes Metab. 2011;13:703-710.
14. Sheffield CA, Kane MP, Busch RS, Bakst G, Abelseth JM, Hamilton RA. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract. 2008;14:285-292.
15. Tzefos M, Olin JL. Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus. Ann Pharmacother. 2010;44:1294-1300.
16. Levin P, Wei W, Wang L, Pan C, Douglas D, Baser O. Combination therapy with insulin glargine and exenatide: Real-world outcomes in patients with type 2 diabetes. Curr Med Res Opin. 2012;28:439-446.
17. Levin PA, Mersey JH, Zhou S, Bromberger LA. Clinical outcomes using long-Term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus. Endocr Pract. 2012;18:17-25.
18. Brixner DI, Said Q, Kirkness C, Oberg B, Ben-Joseph R, Oderda G. Assessment of cardiometabolic risk factors in a national primary care electronic health record database. Value Health. 2007;10:S29-S36.
19. Brixner DI, McAdam-Marx C, Ye X, et al. Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. Diabetes Obes Metab. 2009;11:1122-1130.
20. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130-1139.
21. Efron B, Tibshirani R. An Introduction to the Bootstrap. New York, NY: Chapman & Hall/CRC, 1993.
22. Agresti A. Categorical Data Analysis. 2nd ed. Hoboken, NJ: Wiley-Interscience, 2002.